AP2014007761A0 - Compositions and methods for antibodies targeting factor P - Google Patents

Compositions and methods for antibodies targeting factor P

Info

Publication number
AP2014007761A0
AP2014007761A0 AP2014007761A AP2014007761A AP2014007761A0 AP 2014007761 A0 AP2014007761 A0 AP 2014007761A0 AP 2014007761 A AP2014007761 A AP 2014007761A AP 2014007761 A AP2014007761 A AP 2014007761A AP 2014007761 A0 AP2014007761 A0 AP 2014007761A0
Authority
AP
ARIPO
Prior art keywords
compositions
methods
antibodies targeting
targeting factor
factor
Prior art date
Application number
AP2014007761A
Other languages
English (en)
Inventor
Christian Carsten Silvester Kunz
Michael Roguska
Ute Jaeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014007761(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AP2014007761A0 publication Critical patent/AP2014007761A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AP2014007761A 2011-12-21 2012-12-17 Compositions and methods for antibodies targeting factor P AP2014007761A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161578458P 2011-12-21 2011-12-21
PCT/IB2012/057394 WO2013093762A1 (en) 2011-12-21 2012-12-17 Compositions and methods for antibodies targeting factor p

Publications (1)

Publication Number Publication Date
AP2014007761A0 true AP2014007761A0 (en) 2014-07-31

Family

ID=47666430

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007761A AP2014007761A0 (en) 2011-12-21 2012-12-17 Compositions and methods for antibodies targeting factor P

Country Status (28)

Country Link
US (3) US9051365B2 (enExample)
EP (2) EP2794656B1 (enExample)
JP (2) JP6231493B2 (enExample)
KR (1) KR102159843B1 (enExample)
CN (2) CN104114576B (enExample)
AP (1) AP2014007761A0 (enExample)
AR (1) AR089393A1 (enExample)
AU (4) AU2012356170B2 (enExample)
BR (1) BR112014015111A2 (enExample)
CA (1) CA2859493A1 (enExample)
CL (2) CL2014001640A1 (enExample)
CO (1) CO6990668A2 (enExample)
CR (1) CR20140303A (enExample)
CU (1) CU20140073A7 (enExample)
EA (1) EA201491214A1 (enExample)
ES (1) ES2728278T3 (enExample)
HK (1) HK1254156A1 (enExample)
IL (1) IL233279B (enExample)
MA (1) MA35740B1 (enExample)
MX (1) MX2014007665A (enExample)
PE (1) PE20150159A1 (enExample)
PH (1) PH12014501410A1 (enExample)
SG (2) SG10201703249PA (enExample)
TN (1) TN2014000258A1 (enExample)
TW (1) TW201339174A (enExample)
UY (1) UY34537A (enExample)
WO (1) WO2013093762A1 (enExample)
ZA (1) ZA201404432B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150799T1 (hr) 2008-08-05 2015-09-11 Novartis Ag Sastavi i postupci za protutijela protiv komplementnog proteina c5
JP6293659B2 (ja) 2011-07-01 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
KR20220061248A (ko) * 2013-07-12 2022-05-12 이베릭 바이오, 인크. 안과적 질환을 치료하거나 예방하기 위한 방법
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016191246A2 (en) * 2015-05-22 2016-12-01 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a prame peptide
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
CA3049806A1 (en) * 2017-01-30 2018-08-02 Alexion Pharmaceuticals, Inc. Monovalent anti-properdin antibodies and antibody fragments
CN111201246B (zh) 2017-07-11 2023-10-27 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
EP3697285A4 (en) * 2017-10-17 2021-06-30 Apeliotus Technologies, Inc. FUNCTIONAL BIOMARKERS FOR STATIN THERAPY IN AGE-RELATED MACULAR DEGENERATION (AMD)
GB2569144B (en) * 2017-12-06 2021-06-16 Proimmune Ltd Method for screening the activity of mutated expressed polypeptides
CA3083113A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
MY206244A (en) 2018-05-18 2024-12-05 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
US20220056115A1 (en) * 2018-09-17 2022-02-24 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
US20220252575A1 (en) * 2019-03-29 2022-08-11 Public University Corporation Yokohama City University Screening method and toxicity evaluation method
CA3204091A1 (en) 2020-12-08 2022-06-16 Infinity Pharmaceuticals, Inc. Eganelisib for use in the treatment of pd-l1 negative cancer

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5506247A (en) 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE203767T1 (de) 1992-08-21 2001-08-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CN1117155C (zh) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
JP2000516082A (ja) 1996-02-02 2000-12-05 ヘーモプロベ ベー．フェー． ペプチド基質の補体転換酵素の切断を用いた生体物質による補体の活性化測定法
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
AU736707B2 (en) 1997-06-11 2001-08-02 Anaphore, Inc. Trimerising module
EP2380906A2 (en) 1997-06-12 2011-10-26 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
WO1999010009A1 (en) 1997-08-26 1999-03-04 Gliatech Inc. A process for inhibiting complement activation via the alternative pathway
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
AU3704500A (en) 1999-02-19 2001-01-22 University Of Iowa Research Foundation, The Diagnostics and therapeutics for arterial wall disruptive disorders
EP1804064A1 (en) 1999-02-19 2007-07-04 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DK1212422T3 (da) 1999-08-24 2007-07-02 Medarex Inc Humane CTLA-4-antistoffer og anvendelserne deraf
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
WO2001079444A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc Albumin fusion proteins
AU2001261103B2 (en) 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
WO2001084144A1 (en) 2000-05-04 2001-11-08 Jussi Halleen Method for in vitro screening of drug candidates useful for the prevention of bone resorption
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
EP1186299A1 (en) 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
PT1325033E (pt) 2000-10-10 2010-04-15 Genentech Inc Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2002086085A2 (en) 2001-04-24 2002-10-31 Bayer Corporation Human timp-1 antibodies
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
EP1421203A4 (en) 2001-05-17 2005-06-01 Diversa Corp NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
RU2377253C2 (ru) 2002-12-02 2009-12-27 Амген Фремонт,Инк. Антитела, специфичные к фактору некроза опухолей, и их применение
WO2004075838A2 (en) 2003-02-21 2004-09-10 Rikshospitalet-Radiumhospitalet Hf Method and compositions for the treatment of meconium aspiration syndrome
JP2006518749A (ja) 2003-02-21 2006-08-17 タノックス インコーポレーテッド 虚血再灌流障害に伴う組織損傷を予防及び治療するための方法
WO2004103288A2 (en) 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
CA2524534C (en) 2003-05-15 2012-12-11 Sek Chung Fung Methods and compositions for the prevention and treatment of sepsis
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US7514539B2 (en) 2004-04-26 2009-04-07 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
EP2529746A1 (en) 2005-06-06 2012-12-05 Girish J. Kotwal Methods for treatment or prophylaxis of reperfusion injury
NZ566915A (en) 2005-10-12 2011-09-30 Morphosys Ag Generation and profiling of human derived therapeutic antibodies specific for human CD38
KR20130137716A (ko) 2005-11-04 2013-12-17 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20070196367A1 (en) 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
PT1991275E (pt) 2006-03-08 2015-02-03 Archemix Llc Aptâmeros de ligação ao complemento e agentes anti-c5 úteis no tratamento de distúrbios oculares
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
US9023831B2 (en) * 2007-04-24 2015-05-05 Novelmed Therapeutics, Inc. Methods and compositions of inhibiting complement and cellular activation with Dextran Sulfate
WO2008154018A2 (en) 2007-06-11 2008-12-18 The Trustees Of The University Of Pennsylvania Properdin modulation of alternative pathway and uses thereof
AU2008293487A1 (en) 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
PL2262831T3 (pl) * 2008-03-03 2015-08-31 Novelmed Therapeutics Inc Przeciwciała przeciwko properdynie
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
EP2313137B1 (en) * 2008-08-04 2017-10-11 Fisher & Paykel Healthcare Limited Respiratory mask sealing interface
HRP20150799T1 (hr) * 2008-08-05 2015-09-11 Novartis Ag Sastavi i postupci za protutijela protiv komplementnog proteina c5
CN103068396B (zh) * 2010-03-02 2016-07-06 诺沃姆德治疗公司 抑制c5和备解素相互作用的抗-备解素抗体在制备抑制交替途径活化的药剂中的用途
CN103003302B (zh) * 2010-03-10 2015-09-30 诺沃姆德治疗公司 人源化和嵌合抗-备解素抗体
RU2743409C2 (ru) * 2011-04-08 2021-02-18 Юниверсити Оф Лестер Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента
JP6293659B2 (ja) 2011-07-01 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p

Also Published As

Publication number Publication date
KR20140117411A (ko) 2014-10-07
SG10201703249PA (en) 2017-05-30
US9051365B2 (en) 2015-06-09
UY34537A (es) 2013-07-31
CR20140303A (es) 2015-01-16
CN106831985A (zh) 2017-06-13
EP2794656A1 (en) 2014-10-29
JP6231493B2 (ja) 2017-11-15
EA201491214A1 (ru) 2015-02-27
AU2018219993A1 (en) 2018-09-06
JP6486407B2 (ja) 2019-03-20
US10865237B2 (en) 2020-12-15
NZ626296A (en) 2016-12-23
EP2794656B1 (en) 2019-02-27
US20180327486A1 (en) 2018-11-15
TN2014000258A1 (en) 2015-09-30
CA2859493A1 (en) 2013-06-27
MA35740B1 (fr) 2014-12-01
AU2016203134B2 (en) 2018-05-31
CN104114576B (zh) 2017-04-05
PE20150159A1 (es) 2015-02-08
ES2728278T3 (es) 2019-10-23
TW201339174A (zh) 2013-10-01
IL233279B (en) 2020-10-29
JP2015503909A (ja) 2015-02-05
JP2017192387A (ja) 2017-10-26
PH12014501410A1 (en) 2014-09-22
HK1254156A1 (en) 2019-07-12
SG11201403416TA (en) 2014-07-30
ZA201404432B (en) 2015-09-30
AU2020203047A1 (en) 2020-05-28
KR102159843B1 (ko) 2020-09-24
IL233279A0 (en) 2014-08-31
CN104114576A (zh) 2014-10-22
MX2014007665A (es) 2015-03-05
WO2013093762A1 (en) 2013-06-27
NZ721643A (en) 2020-05-29
AU2016203134A1 (en) 2016-06-02
AU2012356170A1 (en) 2014-07-10
AR089393A1 (es) 2014-08-20
CO6990668A2 (es) 2014-07-10
US20150158936A1 (en) 2015-06-11
AU2012356170B2 (en) 2016-06-16
CL2014001640A1 (es) 2014-12-05
CL2016001256A1 (es) 2016-10-28
US9988440B2 (en) 2018-06-05
US20130295102A1 (en) 2013-11-07
CU20140073A7 (es) 2014-12-26
EP3330288A1 (en) 2018-06-06
BR112014015111A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL276234B (en) Antibody compositions
IL274846A (en) Formulation for anti-antibody alpha 4 in cell 7
IL233279A0 (en) Preparations and methods for antibodies against factor p
IL267668B (en) Formulation for anti-antibody alpha 4 in cell 7
IL271305B (en) Anti-ntb–a antibodies and related compositions and methods
ZA201602366B (en) Compositions and methods for antibodies targeting epo
SG10201602218VA (en) Novel fuel compositions and methods for making same
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
IL232213A0 (en) Antibody Formulations and Methods
ZA201306316B (en) Methods and compositions for preparing noribogaine from voacangine
ZA201308892B (en) Compositions and methods
EP2734646A4 (en) COMPOSITIONS AND METHODS FOR SELECTING APTAMERS
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
GB201116340D0 (en) Compositions and methods